A recent study published in the Lancet indicates that Alzheimer’s disease might be detectable in middle age, showing early signs of memory issues. Researchers explored the potential of a blood test in predicting the onset of dementia, long before noticeable symptoms manifest.
The study analyzed 1,350 individuals without dementia, aged around 61, for biomarkers associated with the accumulation of amyloid and tau proteins in the brain, common in Alzheimer’s patients. Out of the participants, 86 exhibited elevated levels of these biomarkers and displayed lower performance in cognitive tests related to memory and cognitive speed.
Prof. Kristine Yaffe from the University of California highlighted the significance of blood tests in targeting preventive measures and clinical trials to delay or prevent dementia onset. The findings suggest that Alzheimer’s disease could initiate decades before symptoms appear, emphasizing the potential utility of plasma biomarkers for early detection.
Although it remains uncertain whether individuals with amyloid and tau biomarkers will develop Alzheimer’s, ongoing research aims to understand the role of these proteins in disease progression. Efforts are underway to develop an effective blood test for dementia diagnosis, with the NHS initiating a £10 million clinical trial, the ‘Blood Biomarker Challenge’ project.
Moreover, clinical trials for drugs that could impede disease advancement are in progress, emphasizing the importance of administering treatments during the early stages of Alzheimer’s. Another study in the Lancet introduced a novel approach utilizing brain scans to identify tau protein tangles before symptoms arise, showcasing promising advancements in early disease detection.
Dr. Jacqui Hanley from Alzheimer’s Research UK emphasized the significance of detecting Alzheimer’s-related biological changes early in life, enabling participation in treatment studies. Identifying Alzheimer’s sooner could provide opportunities for early intervention and access to disease-modifying treatments, which are more effective in the early stages.
With approximately a million Britons currently living with dementia, estimates suggest a rise to 1.4 million by 2040, with Alzheimer’s comprising the majority of cases. The research underscores the potential of blood tests in detecting abnormal Alzheimer’s markers at a younger age, contributing vital insights for future monitoring and treatment strategies.
